Attovia Therapeutics (ATTO) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($744.6 million vs $734.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | VSTM |
|---|---|---|
| Share price | $16.31 | $8.11 |
| Market cap | $744.57M | $734.47M |
| 1-day change | -0.67% | -1.88% |
| YTD return | — | +7.06% |
| 1-year return | — | -8.17% |
| 5-year return | — | -75.05% |
| EPS (TTM) | $-2.74 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $10.82 |
| 52-week low | $15.48 | $3.43 |
| Distance from 52-week high | -41.75% | -25.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +158.74% | +80.89% |
| Average volume | 458.24K | 2.29M |
| Shares outstanding | 45.65M | 90.56M |
| Employees | 44 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
ATTO vs VSTM FAQ
Which is bigger, Attovia Therapeutics or Verastem?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $744.57M compared with $734.47M for Verastem (VSTM).
Are Attovia Therapeutics and Verastem in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Attovia Therapeutics and Biotechnology: Pharmaceutical Preparations for Verastem.